This study is looking at a treatment approach for women with advanced ovarian, primary peritoneal, or fallopian tube cancer (Stage III or IV). It's testing if adding heated intraperitoneal chemotherapy (HIPEC) with Cisplatin during surgery, followed by a drug called Niraparib, can help prevent the cancer from coming back. You might be eligible if you have a specific type of cancer (high-grade serous or endometrioid epithelial) and are planning to have chemotherapy before surgery. The main goal is to see how long people live without their cancer progressing. The study is planning to enroll 220 participants, but its current status is unclear.

Study design

This interventional study plans to enroll 220 women. Participants will be randomized to receive heated intraperitoneal chemotherapy (HIPEC) with Cisplatin or no HIPEC during surgery.

What's involved

You will receive standard chemotherapy before surgery. After surgery, you will be randomized to receive HIPEC with Cisplatin or no HIPEC, and then take Niraparib. Your health will be monitored for up to 8 years.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed from enrollment until disease progression or death, or date of last contact, for up to 8 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.